Every Form 4 that Lifeward Ltd. (LFWD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow LFWD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LFWD filings page.
Lifeward Ltd. (symbol: LFWD) is the issuer of record for a Form 4 filing submitted to the SEC. Zamir Haggai reported acquisition or exercise transactions in this Form 4 filing.
Lifeward Ltd. (LFWD) reported that director Zamir Haggai received an equity award of 6,711 ordinary shares on August 14, 2026. The award represents restricted stock units granted under Lifeward’s 2025 Incentive Compensation Plan and was reported at a per-share price of $0.00 as a compensation grant.
The 6,711 RSUs vest ratably in four equal quarterly installments starting on the August 14, 2026 grant date, and Haggai’s directly held reported position after the grant is 6,711 ordinary shares, reflecting this new award.
Lifeward Ltd. (symbol: LFWD) is the issuer of record for a Form 4 filing submitted to the SEC.
Lifeward Ltd. (symbol: LFWD) is the issuer of record for a Form 4 filing submitted to the SEC.
Rose Keith Dale reported acquisition or exercise transactions in this Form 4 filing.
Lifeward Ltd. reported that Chief Medical Officer Rose Keith Dale received an equity award of 15,000 ordinary shares in the form of restricted stock units. The RSUs were granted on May 1, 2026 under the company’s 2025 Incentive Compensation Plan.
The RSUs vest in four equal annual installments starting on the grant date, meaning a portion becomes deliverable each year over four years as long as vesting conditions are met. Following this award, Dale is shown as beneficially owning 17,083 ordinary shares directly.
Lifeward Ltd. director Sigsbee William Mark reported an equity compensation grant. He received 11,485 ordinary shares in the form of restricted stock units at a price of $0.00 per share, bringing his direct holdings reported in this filing to 11,485 shares.
The 11,485 RSUs were granted on March 25, 2026 under Lifeward’s 2025 Incentive Compensation Plan. These RSUs vest in four equal quarterly installments, starting three months after the grant date, meaning the award converts into shares gradually over a one‑year period if service conditions are met.
Rozenbaum Moshe H reported acquisition or exercise transactions in this Form 4 filing.
Lifeward Ltd. director Moshe H Rozenbaum reported an equity compensation grant of 11,485 ordinary shares in the form of restricted stock units (RSUs). The award was granted on March 25, 2026 under the company’s 2025 Incentive Compensation Plan at a grant price of $0.0000 per share.
The 11,485 RSUs vest ratably in four equal quarterly installments starting three months from the grant date, meaning the director earns the shares over time rather than all at once. After this grant, Rozenbaum’s reported direct holdings total 11,485 ordinary shares.
Lifeward Ltd. reported that Chief Financial Officer Adar Almog received a grant of stock options on 39,934 ordinary shares of the company. The options have an exercise price of $6.53 per share and expire on March 25, 2036.
The grant vests over four years, with 25% of the underlying shares vesting on March 25, 2027, and the remaining shares vesting in equal monthly installments over the following 36 months, contingent on continued service. Following this grant, Almog holds options to acquire 39,934 shares, reflecting routine, compensation-related equity rather than an open-market share purchase.
Lifeward Ltd. President and CEO Grant William Mark received a grant of stock options covering 172,698 ordinary shares. The options have an exercise price of $6.53 per share and expire on March 25, 2036.
The award vests over four years, with 25% of the underlying shares vesting on March 25, 2027. The remaining 75% vests in equal monthly installments over the following 36 months, contingent on his continued service, with potential acceleration under the applicable plan and grant terms.
Reznick Yehuda reported acquisition or exercise transactions in this Form 4 filing.
Lifeward Ltd. director Yehuda Reznick reported an equity compensation grant rather than a market trade. He received 7,657 ordinary shares in the form of restricted stock units granted on March 25, 2026 under the 2025 Incentive Compensation Plan. These RSUs vest in four equal quarterly installments starting three months after the grant date, and his direct holdings following the grant total 7,657 shares.
Lifeward Ltd. director Nadav Kidron received an equity award valued in shares rather than cash. On the grant date of March 25, 2026, he was granted 7,657 restricted stock units (RSUs) under the company’s 2025 Incentive Compensation Plan at no cash purchase price.
The RSUs convert into ordinary shares in four equal quarterly installments, beginning three months after the grant date. Following this award, Kidron’s reported direct holdings total 7,657 ordinary shares, reflecting the shares issuable upon vesting of this initial RSU grant.
Kidron Miriam reported acquisition or exercise transactions in this Form 4 filing.
Lifeward Ltd. director Miriam Kidron received a grant of 7,657 ordinary shares through restricted stock units under the company’s 2025 Incentive Compensation Plan. These RSUs vest in four equal quarterly installments beginning three months after the March 25, 2026 grant date, aligning compensation with ongoing service.
Lifeward Ltd. reported an insider equity award to one of its officers. The company granted 50,000 ordinary shares, par value NIS 1.75 per share, in the form of restricted stock units (RSUs) on December 11, 2025 under its 2025 Incentive Compensation Plan.
The RSUs vest ratably in four equal annual installments starting on the grant date, meaning the officer receives one quarter of the shares each year as they vest. The transaction is coded as an acquisition at a stated price of $0, reflecting an equity compensation award rather than a market purchase.
Following this grant, the reporting person beneficially owns 96,067 ordinary shares, held directly. The filing is made by a single reporting person, who serves as VP of Market Access & Strategy at Lifeward Ltd.